ST八菱(002592.SZ)擬處置控股子公司弘潤天源51%股權
格隆匯 12 月 30日丨ST八菱(002592.SZ)公佈,公司於2019年以現金支付方式作價9.08億元收購北京弘潤天源基因生物技術有限公司(“弘潤天源”)51%股權(“前次交易”),並自2019年6月起將弘潤天源納入公司合併報表。併購後,弘潤天源經營狀況持續惡化,尤其是2020年初以來因受疫情影響,營業收入大幅下跌,經營業績遠達不到預期,並且在經營中出現了違規擔保、資金佔用等重大違規行為,經營風險較高,對公司造成了重大不利影響。
為降低公司經營風險,防止虧損進一步擴大,公司擬對持有的弘潤天源51%股權進行處置。
公司於2020年12月30日召開第六屆董事會第五次會議審議通過《關於擬處置控股子公司北京弘潤天源基因生物技術有限公司51%股權的議案》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.